Systolic Pressure Efficacy and Safety Trial of Alagebrium (SPECTRA)
Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This study comprises a 3- to 6-week hydrochlorothiazide run in phase, followed by a 12 week
double-blind treatment phase, followed by a 2 week single-blind follow-up hydrochlorothiazide
treatment phase. The combined total duration of patient participation is approximately 17-20
weeks. Four double-blind treatment groups approximately equal in size (98) will comprise the
study population: placebo or various alagebrium dose groups (10, 50, or 150 mg/day).